SZABO SCANDIC

Part of Europa Biosite

# Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

## Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand


**SZABO-SCANDIC HandelsgmbH**

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

# Anti-Rat CD152 (CTLA-4) Monoclonal Antibody

| Catalogue# | Format | Size | Concentration | Isotype Control |
|---|---|---|---|---|
| **CL090AP** | Purified | 250µg | 1.0 mg/ml | CLCMG100 |
| **CL090LE** | Low Endotoxin | 500µg | 1.0 mg/ml | CLCMG100 |
| **CL090B/-5** | Biotin | 100µg/500µg | 0.1 mg/ml | CLCMG115 |
| **CL090F/-5** | FITC | 100µg/500µg | 0.1 mg/ml | CLCMG101 |
| **CL090PE/-4** | PE | 50µg/200µg | 0.1 mg/ml | CLCMG104 |

Isotype: Mouse IgG1

## DESCRIPTION:

Cedarlane's anti-rat CD152 monoclonal antibody is specific for the cytotoxic T lymphocyte-associated protein 4 (CTLA-4), also called CD152. This antigen is known to be the receptor for B7 ligands (CD80 and CD86) present on antigen presenting cells. A subset of CD4 T cells expressing CD25 and CTLA-4 has been recognized as a potent suppressor cell population, counteracting autoimmunity and inflammation. These 'regulatory' T cells (Treg) which produce the anti-inflammatory cytokine interleukin-10 (IL-10) but not IL-2, are able to suppress the proliferation of costimulated CD25- negative indicator cells. The capacity of these naturally occurring regulatory T cells to suppress autoimmunity and inflammation suggests that therapies which activate and expand this subset could become extremely effective treatments for these immune-pathological disorders.

This clone has been tested in flow cytometry. In rats, the constitutive expression of CTLA-4 at the level detectable by flow cytometry is restricted to the CD25+ subset of CD4 T cells and thymocytes.

## PRESENTATION:

**Purified**: Purified IgG buffered in PBS and 0.02% $NaN_3$. (Purified from ascitic fluid via Protein G Chromatography). For maximum recovery of contents, spin down tube before use.
**LE:** Purified Ig buffered in PBS, no preservative, 0.2µm sterile filtered. (Purified from cell culture supernatant via Protein G Chromatography)
**Biotin, FITC** and **PE**: Biotin/FITC/PE conjugated IgG buffered in PBS, 0.02% $NaN_3$ and EIA grade BSA as a stabilizing protein to bring total protein concentration to 4-5 mg/ml.

## STORAGE/STABILITY:

For all formats, store at 4°C. DO NOT FREEZE **PE** conjugates. For long term storage (**Purified, LE, Biotin** and **FITC**), aliquot and freeze unused portion at -20°C in volumes appropriate for single usage. Avoid freeze/thaw cycles.

*Continued Overleaf…..*



**In CANADA: Toll Free: 1-800-268-5058**
4410 Paletta Court, Burlington, ON L7L 5R2 ph: (289) 288-0001, fax: (289) 288-0020
e-mail: general@cedarlanelabs.com

**In the USA: Toll Free: 1-800-721-1644**
1210 Turrentine Street, Burlington, NC 27215 ph: (336) 513-5135, fax: (336) 513-5138
e-mail: service@cedarlanelabs.com

**SPECIFICATIONS:**

Clone: WKH 203

Hybridoma Production:

Immunization: Immunogen: Purified rCTLA-4hlg fusion protein
Donor: BALB/c mice spleen cells
Fusion Partner: X63 Ag8.653 myeloma cells

Specificity: Rat CD152

**TEST RESULTS:**

Tissue Distribution by Flow Cytometry Analysis:

Rat Strain: Wistar
Cell Concentration: $1x10^6$ cells per test
Antibody Concentration Used: 2.0 µg/$10^6$ cells
* (T cells isolated with CL102 Cedarlane's Rat T Cell Recovery Column Kit)

| Cell Source | Percentage of cells stained above control: |
|---|---|
| Lymph Node (on CD25+ cells) | 73.1% |
| Spleen (on CD25+ cells) | 87.3% |
| Thymus (on CD25+ cells) | 76% |



Anti-Rat CD152
Cell Source: Spleen

**N.B. Appropriate control samples should always be included in any labeling studies.**
*** For optimal results in various applications, it is recommended that each investigator determine dilutions appropriate for individual use.**

**REFERENCES:**

1. Elflein, K., Rodriguez-Palmero, M., Kerkau, T., and T. Hunig. (2003) Immunobiology. 102, 1764 -1770. Rapid recovery from T lymphopenia by CD28 superagonist therapy.
2. Lin, C.-H., and T. Hunig. (2003) Eur. J. Immunol. 33, 626-638. Efficient expansion of regulatory T cells *in vitro* and *in vivo* with a CD28 superagonist.

**FOR RESEARCH USE ONLY**



CS 08/19/2016